Imaging bone metastases in breast cancer: Evidence on comparative test accuracy

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 834-843

  Houssami, N ^a   Costelloe, C M ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone metastases; Breast cancer; Cancer staging; Imaging; Positron emission tomography; Sensitivity and specificity

Indexed keywords

ADULT; AGED; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; BREAST CANCER; CANCER LOCALIZATION; CANCER RELAPSE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; WHOLE BODY MRI;

BONE NEOPLASMS; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; FEMALE; HUMANS; PREVALENCE; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY;

EID: 84859487799     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr397     Document Type: Review

References (44)

1. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22: 2942-2953.
2. Whitlock JP, Evans AJ, Jackson L, Chan SY, Robertson JF. Imaging of metastatic breast cancer: distribution and radiological assessment at presentation. Clin Oncol (R Coll Radiol) 2001; 13: 181-186.
3. Costelloe CM, Rohren EM, Madewell JE et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 2009; 10: 606-614.
4. Roberts CC, Daffner RH, Weissman BN et al. ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol 2010; 7: 400-409.
5. Arano Y. Recent advances in 99mTc radiopharmaceuticals. Ann Nucl Med 2002; 16: 79-93.
6. Loeffler RK, DiSimone RN, Howland WJ. Limitations of bone scanning in clinical oncology. JAMA 1975; 234: 1228-1232.
7. Han LJ, Au-Yong TK, Tong WC, Chu KS, Szeto LT, Wong CP. Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain. Eur J Nucl Med 1998; 25: 635-638.
8. Romer W, Nomayr A, Uder M, Bautz W, Kuwert T. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med 2006; 47: 1102-1106.
9. Ndlovu X, George R, Ellmann A, Warwick J. Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies? Nucl Med Commun 2010; 31: 659-665.
10. Avrahami E, Tadmor R, Dally O, Hadar H. Early MR demonstration of spinal metastases in patients with normal radiographs and CT and radionuclide bone scans. J Comput Assist Tomogr 1989; 13: 598-602.
11. Frank JA, Ling A, Patronas NJ et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. AJR Am J Roentgenol 1990; 155: 1043-1048.
12. Ma J, Costelloe CM, Madewell JE et al. Fast dixon-based multisequence and multiplanar MRI for whole-body detection of cancer metastases. J Magn Reson Imaging 2009; 29: 1154-1162.
13. Smith TA. FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun 1998; 19: 97-105.
14. Veit-Haibach P, Antoch G, Beyer T et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol 2007; 80: 508-515.
15. Bossuyt PM, Irwig L, Craig J, Glasziou P. Comparative accuracy: assessing new tests against existing diagnostic pathways. [erratum appears in BMJ. 2006 Jun 10;332(7554):1368]. BMJ 2006; 332: 1089-1092.
16. Leeflang MM, Bossuyt PM, Irwig L. Diagnostic test accuracy may vary with prevalence: implications for evidence-based diagnosis. J Clin Epidemiol 2009; 62: 5-12.
17. Bossuyt PM, Reitsma JB, Bruns DE et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003; 138: W1-W12.
18. Houssami N, Irwig L, Loy C. Accuracy of combined breast imaging in young women. Breast 2002; 11: 36-40.
19. Bossuyt PM, Reitsma JB, Bruns DE et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Radiology 2003; 226: 24-28.
20. Heusner TA, Kuemmel S, Koeninger A et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 2010; 37: 1077-1086.
21. Morris PG, Lynch C, Feeney JN et al. Integrated positron emission tomography/ computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol 2010; 28: 3154-3159.
22. Fuster D, Duch J, Paredes P et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008; 26: 4746-4751.
23. Mahner S, Schirrmacher S, Brenner W et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 2008; 19: 1249-1254.
24. Bristow AR, Agrawal A, Evans AJ et al. Can computerised tomography replace bone scintigraphy in detecting bone metastases from breast cancer? A prospective study. Breast 2008; 17: 98-103.
25. Schmidt GP, Baur-Melnyk A, Haug A et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol 2008; 65: 47-58.
26. Aslan S, Cetin B, Akinci M, Cetin M, Yucekule N, Cetin A. Computed tomography in detecting bone metastases of breast carcinoma. Is it better than plain x-ray? Saudi Med J 2006; 27: 1326-1328.
27. Abe K, Sasaki M, Kuwabara Y et al. Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 2005; 19: 573-579.
28. Nakai T, Okuyama C, Kubota T et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005; 32: 1253-1258.
29. Uematsu T, Yuen S, Yukisawa S et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol 2005; 184: 1266-1273.
30. Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 2004; 14: 99-105.
31. Gallowitsch HJ, Kresnik E, Gasser J et al. F-18 fluorodeoxyglucose positronemission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003; 38: 250-256.
32. Dose J, Bleckmann C, Bachmann S et al. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002; 23: 857-864.
33. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002; 128: 325-328.
34. Ohta M, Tokuda Y, Suzuki Y et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 2001; 22: 875-879.
35. Altehoefer C, Ghanem N, Hogerle S, Moser E, Langer M. Comparative detectability of bone metastases and impact on therapy of magnetic resonance imaging and bone scintigraphy in patients with breast cancer. Eur J Radiol 2001; 40: 16-23.
36. Carlson RW, Allred DC, Anderson BO et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2009; 7: 122-192.
37. Khatcheressian JL, Wolff AC, Smith TJ et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 24: 5091-5097.
38. National Collaborating Centre for Cancer. (developed for NICE). Advanced Breast Cancer: Diagnosis and Treatment (full guideline) 2009; www.guidance.nice.org.uk (5 January 2011, date last accessed).
39. Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M. ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v15-v19.
40. Myers R, Minuk T, Johnston M. the Diagnostic Imaging Guidelines Panel. Diagnostic Imaging in Breast Cancer. Recommendations report, Toronto (ON): Cancer Care Ontario (CCO). 2006; www.cancercare.on.ca (12 December 2010, date last accessed).
41. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004; 140: 189-202.
42. Houssami N, Ciatto S, Irwig L, Simpson JM, Macaskill P. The comparative sensitivity of mammography and ultrasound in women with breast symptoms: an age-specific analysis. Breast 2002; 11: 125-130.
43. KimDS, Hong SH, Choi JY et al. Magnetic resonance imaging diagnoses of bone scan abnormalities in breast cancer patients. Nucl Med Commun 2009; 30: 736-741.
44. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995; 13: 1470-1477.